Pharming Group (NASDAQ:PHAR) Given New $39.00 Price Target at Oppenheimer

Pharming Group (NASDAQ:PHAR) had its price objective increased by equities research analysts at Oppenheimer from $30.00 to $39.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s target price points to a potential upside of 343.94% from the company’s previous close.

Several other equities analysts have also weighed in on PHAR. Jefferies Financial Group initiated coverage on Pharming Group in a report on Monday, December 9th. They set a “buy” rating and a $14.00 target price on the stock. HC Wainwright restated a “buy” rating and issued a $37.00 target price on shares of Pharming Group in a report on Friday.

Pharming Group Stock Up 0.5 %

Shares of Pharming Group stock traded up $0.05 on Friday, hitting $8.79. 1,156 shares of the company traded hands, compared to its average volume of 6,175. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41. Pharming Group has a 12-month low of $6.65 and a 12-month high of $11.80. The company has a 50-day moving average price of $9.05 and a 200 day moving average price of $8.57. The company has a market cap of $597.65 million, a PE ratio of -33.78 and a beta of -0.10.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings results on Thursday, March 13th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. Sell-side analysts predict that Pharming Group will post -0.2 earnings per share for the current year.

Institutional Trading of Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its stake in Pharming Group (NASDAQ:PHAR) by 16.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 47,997 shares of the company’s stock after acquiring an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.07% of Pharming Group worth $483,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.